Evidence map›Paper›PMID 41025596›Full record

ReviewDisease models & mechanisms2025

Engineered bacteriophages for therapeutic and diagnostic applications.

Kandas Traore, Damien Seyer, Agnes Mihajlovski, Antonia P Sagona

Abstract readReview
In one paragraph

Review in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. DecipheringMicroorganisms · 2026
    Review
  4. Bacteriophages targetingFrontiers in microbiology · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kandas TraoreCY Cergy Paris Université, ERRMECe Laboratory, Biomaterials for Health Group, Neuville Sur-Oise 95031, France.
Damien SeyerCY Cergy Paris Université, ERRMECe Laboratory, Biomaterials for Health Group, Neuville Sur-Oise 95031, France.
Agnes MihajlovskiCY Cergy Paris Université, ERRMECe Laboratory, Biomaterials for Health Group, Neuville Sur-Oise 95031, France.ORCID 0000-0002-5626-2021
Antonia P SagonaSchool of Life Sciences, Warwick University, Gibbet Hill Campus, Coventry CV4 7AL, UK.ORCID 0000-0002-0386-2322

Funding

Biotechnology and Biological Sciences Research Council BB/V017217/1Eutopia Foundation EUTOPIA-PhD-2021-0000000140
6 · The paper itself

Abstract

Antimicrobial resistance represents one of the most serious threats to both public health and economic sustainability. One of the promising approaches to address this problem is phage therapy - treatment of pathogenic bacterial infections using bacteriophages. Bacteriophages have a narrow host spectrum of activity, minimal side effects and self-replication at the infection site, which positions them as promising candidates to complement or replace conventional antibiotics. Moreover, they can be easily genetically modified to enhance their effectiveness and safety. In this At a Glance article, we highlight the timely relevance of engineered phages as an innovative solution in a rapidly evolving healthcare landscape. First, we introduce bacteriophages' life cycle, ecology and therapeutic history, emphasizing their role in One Health strategies. Then, we describe advanced engineering techniques that can be used to expand bacteriophages' functionalities. Finally, we discuss innovative applications of engineered bacteriophages in biotechnological applications and as a potential countermeasure for antimicrobial resistance, including serving as a shuttle for delivering genes and drugs to the targeted bacterial and eukaryotic cells, targeting intracellular bacteria, contributing to vaccine development, facilitating advancements in tissue engineering and improving bacteriophages' antibacterial properties.

Indexed as

BacteriophagesGenetic EngineeringPhage TherapyAnimalsBacterial InfectionsHumansAntibiotic resistanceBacteriophagesGenomic engineeringNanomedicine

Identifiers

PMID41025596
PMCPMC12519544

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.